XALKORI

Reason for request

Clinical Benefit

Substantial

The actual benefit is substantial in the second-line treatment of ALK+ advanced non-small cell lung cancer (NSCLC).

Clinical Added Value

moderate

XALKORI provides a moderate improvement in actual benefit (level III) in the treatment strategy of ALK+ advanced non-small cell lung cancer as a second-line therapy and compared with docetaxel or pemetrexed.